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Fifteen years of infrapopliteal arterial
reconstructions with cryopreserved venous
allografts for limb salvage
Caren Randon, MD,a Bart Jacobs, MD,a Frederik De Ryck, MD,a Hilde Beele, MD, PhD,b and
Frank Vermassen, MD, PhD,a Gent, Belgium
Objective: The availability of autologous vein grafts remains the limiting factor in infragenual bypass surgery in many
patients with critical limb ischemia (CLI). Alternatives such as prosthetic conduits are known to have a poor outcome and
most are not resistant to infection. Based on previous experimental work, we started to use cryopreserved saphenous vein
allografts for this indication 15 years ago. To evaluate their outcome, we performed a retrospective study of those
bypasses with distal anastomosis on a crural or pedal vessel.
Methods: Between November 1991 and December 2005, 108 cryopreserved great saphenous vein allografts were
implanted for in 92 patients (42 women, 50 men) with a mean age of 71 years (range, 39-88 years). All patients received
low-dose immunosuppressive therapy for up to 1 year after intervention. Follow-up was conducted until amputation,
death, or the end of the study in March 2007.
Results: Nondiabetic atherosclerosis the cause of CLI in 57%, 41% had diabetes, and 2% had Buerger disease. Forty-one
conduits were performed for primary reconstructions and 67 for redo reconstructions. During a mean follow-up of 26.4
months, 69 occlusions occurred. Primary and secondary patency rates were 56% and 73% at 1 year, 32% and 60% at 3
years, and 17% and 38.5% at 5 years. Survival rates were 87.4% at 1 year and 64.5% at 5 years. At multivariate analysis,
the intake of statins was predictive for improved patency (hazard ratio [HR], 0.09; P .024) and for prolonged survival
(HR, 0.335; P  .045). The presence of diabetes showed a trend for inferior patency (HR, 2.325; P  .116) and for
decreased amputation risk (HR, 0.592; P  .078).
Conclusion: Cryopreserved saphenous vein allografts are a valuable alternative to prosthetic materials when autologous
veins are not available. Our limb salvage and patency rates are higher then those described for prosthetic grafts at the
infrapopliteal level in most studies. Moreover, these grafts are resistant to infection when performed for revascularization
in patients with an infected ulcer. Better graft and patient selection, better graft surveillance and immunologic matching,
and standard use of statins could possibly improve the results even further. Shortage in availability might be a limiting
factor for their widespread use. ( J Vasc Surg 2010;51:869-77.)Critical limb ischemia (CLI) remains the primary
indication for infrapopliteal bypass surgery with the autol-
ogous great saphenous vein (GSV) as the preferred graft
material according to Trans-Atlantic InterSociety Consen-
sus (TASC II).1However, the GSV can not be used in up to
30% of the patients in need of a distal bypass due to
insufficient quality, previous removal, or use for coronary
or peripheral revascularization. Schanzer et al2 confirmed in
patients with CLI that the absence of a good quality autol-
ogous GSV (veins of sufficient length and with a diameter
of more then 3.5 mm) significantly increased the risk for
major amputation. In that study, the 1-year primary and
secondary patency rates (popliteal bypasses included) were
60.5% and 80.1%, for good quality GSV grafts but only
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In two recent meta-analyses, the 1-year primary and sec-
ondary patency rates were 59% and 66.4%3 for prosthetic
grafts and 58.1% and 68.2% for infrapopliteal endovascular
procedures.4
Although these outcomesmight seem acceptable, com-
parison between techniques and materials remains hazard-
ous: prosthetic bypasses are unlikely to be used as a last
resort in patients with bad outflow or overt infection, and
patients in need of a femorocrural bypass often have femo-
ral and popliteal artery occlusion beyond the limits of
endovascular therapy. Moreover, when distal reconstruc-
tions fail and no autologous material is available, 60% end
up with a major amputation, 20% die6 months, and 15%
will need a contralateral major amputation2 years (TASC
II).1 Therefore, the need remains to search for useful
alternatives.
Cryopreserved vascular allografts have long been used
as an alternative conduit, primarily to replace infected pros-
theses, but negative reports on their outcome in infrapop-
liteal revascularizations for CLI tempered their use.5 Two
major problems associated with cadaveric allografts are the
high thrombosis rate and, less frequently, aneurysmal de-
generation.6 The risk for thrombosis is enhanced by rejec-
tion, leading to loss of endothelial lining and function, and
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fibrosis.7 Even the introduction of immunosuppressive
therapy,8 improvement of harvesting techniques and pres-
ervation fluids,9 and the use of anticoagulation therapy10
could not improve the patency rate of these allografts in
most studies.
For almost 2 decades we used cryopreserved GSV allo-
grafts that were procured from deceased donors and
stocked at the tissue bank of our institution. The choice for
cryopreserved human GSV allografts was based on previous
experimental work at our department.7,11 Through careful
graft selection, rigorous preservation technique, and add-
ing low-dose immunosuppressive therapy, we hoped to
improve the outcome results compared with most pub-
lished reports.5 To evaluate our results and for reasons of
quality control, we retrospectively reviewed all cryopre-
served GSV allografts used as an infrapopliteal conduit and
compared the results with those published on venous allo-
grafts.
MATERIAL AND METHODS
This study complied with the Declaration of Helsinki
and was approved by the Ethics Committee of the Univer-
sity Hospital Ghent. All records from patients with chronic
CLI who received a cryopreserved venous allograft for
infrapopliteal arterial reconstruction at our institution be-
tween November 1991 and December 2005 were re-
viewed. CLI is defined as the presence of chronic ischemic
rest pain and nonhealing ulcers or gangrene for 2 weeks
attributable to objectively proven arterial occlusive disease.
The autologous GSV was unavailable due to prior use
in arterial (62%) or coronary revascularizations (31%), or
could not be used due to unsuitable size (3 mm) or
quality (varicosities; 7%) on vein mapping duplex ultra-
sound (DUS) imaging or direct exploration. In our expe-
rience it was rarely possible to find an arm vein of sufficient
quality and length to perform a long bypass. We only used
small saphenous vein (SSV) if small parts of the vein are
necessary for reconstructions, because the SSV conduit is
known for moderate results12 and harvesting both SSVs is
time consuming. Prosthetic grafts with venous cuff were
used on tibial vessels only when the vessel was of sufficient
quality, had a good outflow, and no risk of infection was
present. In other cases, a vein allograft was used.
The allograft GSVs were harvested from deceased mul-
tiorgan donors aged 65 years without history of venous
insufficiency, venous thrombosis, or of trauma or lesion
near the GSV. The minimal accepted diameter of the vein
was 3.5 mm and the minimal length was 30 cm. If possible,
the GSV was harvested from the ankle to the groin. By
selecting and handling the allografts ourselves, we had a
guarantee on the quality of the veins before freezing.
After sterile preservation, they were rinsed and irrigated
with Hanks fluid. All donor veins underwent bacteriologic
and serologic testing for human immunodeficiency virus
and hepatitis C. If any of those tests were positive, the veins
were not used.The allografts were frozen at a controlled rate of 1°C/
min in Hanks solution with 15% dimethylsulfoxide
(DMSO) and preserved in liquid nitrogen (196°C) at our
hospital tissue bank. No antibiotics were added. Before use,
the allografts were slowly thawed in a warm water bath at
20°C and a control bacterial culture was taken before
implantation. The veins were rinsed with Hanks solution
containing decreasing concentrations of DMSO in a four-
step protocol.
Whenever possible, ABO-blood group was matched
between donor and recipient. We did not perform routine
human leukocyte antigen matching because the scarcity of
donors would have prevented from taking this into ac-
count. The Rhesus factor was not considered because it is
not expressed on endothelial cells of veins. At the moment
of implantation, we collected a sample of the cryopreserved
saphenous vein for anatomopathologic study if possible and
also performed a new bacterial test. If this result was posi-
tive (most often Staphylococcus), we just monitored the
patient’s parameters and wound healing. No infected allo-
graft conduits occurred during the study period.
Patient selection. Between November 1991 and De-
cember 2005, 108 cryopreserved GSV allografts were im-
planted on a crural or pedal artery in 92 CLI patients (42
women, 50 men) who were at clinical Rutherford 4 to 6. In
the same time period, 326 tibial or pedal bypasses were
performed. Fifteen patients had chronic rest pain (14%;
Rutherford 4), 74 bypasses (68%) were performed for
nonhealing ulcers or gangrene of the foot (Rutherford 5),
and 19 (18%) for extensive soft-tissue deficit with osteomy-
elitis (Rutherford 6). Nineteen patients had osteomyelitis
before revascularization, 33 (44%) had an infected ulcer
and were taking antibiotics, and 1 patient also had an
infected femoropopliteal prosthesis that was removed dur-
ing surgery. These patients were monitored until March
2007, or until death or major amputation, for graft pa-
tency, limb salvage, and survival.
The patients were a mean age of 71 years (range, 39-88
years), and 20 were aged 80 years. CLI was caused by
nondiabetes atherosclerosis in 57%, diabetes in 41%, and
Buerger disease in 2%. The number of diabetes patients
might be lower then in other studies because we could still
perform an endovascular recanalization in most of our
diabetes patients. Nearly half of the patients had a history of
angina or myocardial infarction, 31% had a preceding cor-
onary bypass grafting operation, and 18% had renal insuf-
ficiency or required dialysis (Table I). Hemodynamic data
were insufficiently available for analysis.
Implantation of the allograft was the first attempt for
distal revascularization in 41 patients (38%). The remaining
67 previously underwent 165 ipsilateral distal revasculariza-
tions (up to 5 procedures in 1 patient). More then one
allograft was implanted in 14 patients. Two patients re-
ceived a concomitant free flap transfer to close a large soft
tissue deficit, and 17 already had undergone a contralateral
major amputation. The plantar arch was absent in 28%, only
partially existing in 69%, and fully patent in 3%. One crural
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vessels with multiple segmental occlusions.
Only ABO compatibility between the donor and the
recipient was taken into account: 86 transplants (80%) were
ABO compatible, 5 had an ABO mismatch, and data were
missing for 17 (before digitalization of the system). All
ABO mismatches were A to O. No composite grafts (com-
bined prosthesis and vein graft) were used. The reconstruc-
tions were performed with the patient under general anes-
thesia. All patients received unfractionated heparin (5000
IU) before graft implantation. Antimicrobial prophylaxis
consisted of first-generation cephalosporins given at the
start of the procedure and every 8 hours afterwards for 24
hours.
Except for seven cases starting from the iliac (n 3) or
the popliteal artery (n  4), all bypass grafts started from
the common or superficial femoral artery. All were im-
planted in the reversed way. The proximal and distal anas-
tomoses were performed in an end to side fashion. The
target vessels were the anterior tibial artery in 32 cases, the
posterior tibial artery in 37, the peroneal artery in 26, and a
pedal artery in 7. Three patients required a jump graft to the
anterior and the posterior tibial artery, and three patients
required a conduit ending on the tibioperoneal trunk (Ta-
ble II). The mean procedure time (with concomitant pro-
cedures in 30%) was 207  90 minute (Table II).
The median hospital stay was 16 days (range 5-364
days for rehabilitation after major amputation). All patients
received low-dose immunosuppressive therapy consisting
of cyclosporine (1.5 mg/kg daily; Neoral, Novartis, Basel,
Switzerland) matching a blood level of 100 to 150 mg/dL
Table I. Risk factors and hazard ratios for occlusion, survi
Factor No. (%)
Occlusion
HR (95% CI)
Hypertension 81 (75) NA
Previous ipsilateral
revascularization 67 (62) 1.399 (0.471-4.151)
Cardiac insufficiency 53 (49) 2.263 (0.376-6.028)
Diabetes 44 (41) 2.325 (0.812-6.653)
Smoking 43 (40) 0.951 (0.539-1.681)
Dyslipidemia (statins) 33 (31) 0.090 (0.011-0.729)
Previous CABG 33 (31) 1.175 (0.677-2.038)
Stroke/TIA 31 (29) 0.992 (0.466-2.113)
Bad runoff 30 (28) 1.629 (0.344-7.710)
Previous minor amputation 22 (20) NA
Osteomyelitis 21 (19) NA
Renal insufficiencyb 19 (18) 1.568 (0.466-5.281)
Previous major amputation 17 (16) NA
Previous aortic surgery 12 (11) NA
Morbid obesity 12 (11) NA
Respiratory insufficiency 11 (10) NA
PTCA 5 (5) 1.051 (0.360-3.069)
ABO incompatibility 5 (5) 0.632 (0.078-5.101)
CABG, Coronary artery bypass grafting; CI, confidence interval; HR, hazar
transient ischemic attack.
aValues of P  .05 are statistically significant.
bSerum creatinine 1.5 mg/dL or on dialysis.for 1 year. Cyclosporine was chosen based on previousexperimental work,8 its working mechanism, and limited
side effects. We assume that at 1 year, host cells have
repopulated the endothelium of the allograft and that the
risk for rejection and subsequent thrombosis is sufficiently
reduced.
Cyclosporine was discontinued in three patients be-
cause of nephrotoxicity, with no effect on the outcome of
the allograft; all three patients died of cardiac comorbidity
early in the follow-up. Some patients complained of gastro-
nd limb salvage
Survival Amputation risk
HR (95% CI) Pa HR (95% CI) Pa
NA . . . NA . . .
NA . . . 1.045 (0.604-1.808) .875
1.520 (0.583-3.961) .391 0.934 (0.532-1.642) .814
1.734 (0.225-13.377) .769 0.592 (0.331-1.060) .078
1.371 (0.521-3.606) .523 0.924 (0.514-1.661) .792
0.335 (0.115-0.977) .045 0.899 (0.521-1.551) .702
1.236 (0.526-2.903) .526 1.337 (0.647-2.764) .434
0.663 (0.191-2.310) .519 1.083 (0.402-2.919) .875
0.891 (0.193-4.114) .882 1.180 (0.551-2.531) .670
NA . . . NA . . .
NA . . . NA . . .
0.289 (0.064-1.315) .108 0.747 (0.383-1.458) .393
NA . . . NA . . .
NA . . . NA . . .
NA . . . NA . . .
NA . . . NA . . .
NA 0.963 (0.218-4.249) .960
0.517 (0.067-3.981) .526 0.525 (0.160-1.725) .525
; NA, not applicable; PTCA, percutaneous transluminal angioplasty; TIA,
Table II. Bypass configuration and adjunctive procedures
No. %
Reconstruction
Femorotibial posterior bypass 35 32.4
Femorotibial anterior bypass 31 28.7
Femoroperoneal bypass 26 24
Popliteopedal bypass 4 3.7
Femorotibial anteroposterior (jump) 3 2.8
Femorotibioperoneal bypass 3 2.8
Femoropedal bypass 3 2.8
Iliotibial post bypass 2 1.9
Iliotibial ant bypass 1 0.9
Adjunctive procedures
Toe or forefoot amputation 13 12
Sympathectomy 12 11
Profundoplasty 5 4.6
Thrombectomy 4 3.7
Iliofemoral bypass 3 2.8
PTA iliac artery 3 2.8
Meshed grafts (STG) 2 1.85
PTA superficial femoral artery 1 0.9
PTA, Percutaneous transluminal angioplasty; STG, split-thickness graft.val, a
Pa
.545
.563
.116
.864
.024
.567
.983
.538
. . .
. . .
.468
.928
.666
d ratiointestinal disorders, but only one patient stopped taking
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treated in-hospital with low-molecular-weight heparin;
75% were switched to warfarin (62.5%) or clopidogrel
(12.5%), and the remaining were prescribed low-dose
aspirin.
The patients were monitored with ankle-brachial index
measurement and serial DUS scanning of the arterial recon-
struction at 1, 3, 6, and 12 months, and then annually. A
graft was considered patent when patent on DUS scanning
or if a pulse was palpable over the graft or the outflow artery
and if the peripheral perfusion index was maintained at the
postoperative level. An angiography was performed when a
DUS scan showed a significant abnormality, and if neces-
sary, a reintervention.
Clinical end points. Primary (assisted) and secondary
patency, limb salvage, and survival were defined as end
points of this study. Primary (assisted) patency was defined
as patency until the first graft occlusion. Secondary patency
was defined as patency (restoration of flow in the graft)
from the first occlusion treated with thrombectomy or
thrombolysis with most of the original allograft and at least
one anastomosis retained in continuity. We considered
limb salvage successful when the plantar stand was main-
tained, and an amputation above the ankle was considered
a failure.
Statistics. All preoperative and postoperative data
were obtained from patient files at our department and
from the referring physicians. Descriptive data are pre-
sented as the mean value  SD. Statistical analysis was
performed with SPSS 16.0 (SPSS Inc, Chicago, Ill)
SigmaStat 3.1 software (Systat Software Inc, San Jose,
Calif). Cumulative patient survival, limb salvage, and graft
patency were assessed by the Kaplan-Meier method. Risk
factors for patency, limb salvage, and death were estimated
with univariate and multivariate analysis using the log-rank
test. Hazard ratios (HR) to evaluate time to event variables
were calculated with the Cox proportional hazard model
with 95% confidence levels. The P  .05 level was used to
determine statistical significance.
RESULTS
Early results. Early complications were hemorrhage
from a tear in the allograft vein or from a dehiscence of a
side branch of the vein in 3 patients, anastomotic pseudo-
aneurysm formation in 3, major stroke in 2, temporary
dialysis in 2, and permanent dialysis in 2 patients with
pre-existing poor renal function. Five patients (4.6%) died
in the hospital after revascularization: four of a major
myocardial infarction and 1 of duodenal ulcer bleeding.
During the first 30 days, in 18 grafts occluded as a result of
technical problems or poor distal runoff. Ten patients un-
derwent a major amputation and the other eight were
treated with a thrombectomy. Three of those eight patients
required amputation1 year and another two died during
follow-up. Twelve patients died before complete healing of
the ulcers but all had relief of intractable pain (Table III).
Late results. Long-term follow-up was available for
93 reconstructions with a mean follow up time of 26.4 32 months (range, 1-180 months). Of the 21 patients
(22.6%) who died after a mean of 31 35months, 7 deaths
were related to a surgical procedure or major amputation.
The cumulative patient survival at 1, 3, and 5 years was thus
87.4%, 69.4%, and 64.5% (Fig 1).
A total of 32 occlusions occurred after a mean
follow-up of 14  15 months, and 18 of these resulted in
leg loss. The limb salvage rate at 1, 3, and 5 years was 85%,
70%, and 64% (Fig 1). Most of the amputations had to be
performed in the first postoperative month. One-third of
the patients with previous ipsilateral femorodistal revascu-
larizations required a major amputation, which was not
significantly different from those without prior bypass.
Stenosis at the proximal or distal anastomosis or shrink-
age of the diameter of the vein due to fibrosis caused 14
failures. Seven procedures were performed on failing grafts
to maintain patency: six patients were treated with a percu-
taneous angioplasty for a critical stenosis without clinical
symptoms, and an aneurysmal degeneration was excised in
one patient (Table III). This brought the primary and the
primary assisted patency rates at 6 months to 66.6% and
72.3%, and at 1, 3, and 5 years 49.9% and 55.7%, 26.4% and
32%, and 11.1% and 17.3%, respectively.
Five grafts were rescued with a second thrombectomy,
and nine patients needed a new femorodistal bypass on a
more distal target vessel. The secondary patency rate at 1, 3,
and 5 years was 73%, 60%, and 38.5% (Fig 2). Infection of
the vein allograft was not observed.
At multivariate analysis, the intake of statins (31 of the
33 patients with dyslipidemia) was an independent positive
predictive risk factor for improved patency (HR, 0.09; P
.024) and for prolonged survival (HR, 0.335; P  .045).
The presence of diabetes showed trends for worse patency
(HR, 2.325; P  .116) and for decreased amputation risk
(HR, 0.592; P  .078). All graft failures that ended in
major amputation were in patients with limited runoff.
Amputation was performed after a first occlusion in 7
patients and after a second occlusion in 11 patients; never-
theless, runoff had no statistically significant effect on pa-
tency and limb salvage. Blood groupmismatch was also not
a significant risk factor for patency or limb salvage (Table I).
Contrary to the findings of many other authors, a previ-
ously failed ipsilateral reconstruction was not a risk factor
for occlusion and a failed bypass was not a risk factor for
Table III. Procedures performed to salvage failing or
failed grafts
Procedure No. %
Early thrombectomy 8 7.4
Late thrombectomy 5 4.6
New femorodistal bypass 9 8.33
Preemptive PTA for critical stenosis 6 5.56
Excision of aneurysmal degeneration 1 0.093
PTA, Percutaneous transluminal angioplasty.survival.
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The creation of femorodistal bypasses on crural or
pedal vessels in the absence of suitable autologous saphe-
nous vein remains a major challenge in modern vascular
surgical practice. Prosthetic conduits have yielded inferior
results in this indication and are prone to infection in the
presence of infected ulcers.13 Adjuncts such as vein cuffs or
arteriovenous shunts have not consistently proven to im-
prove the results.14 Although Albers et al3 reported poly-
tetrafluoroethylene graft below knee patency rates of 59%
after 1 year and 30.5% after 5 years in a meta-analysis, these
figures probably do not reflect real-world experience and
results are due to publication bias. Dardik et al15 reported a
4-year secondary patency rate of 37% with human umbilical
vein grafts in below knee bypasses (including the in-
fragenual popliteal artery), but these grafts are no longer
available. A few articles reported the use of upper extremity
veins and SSVs as an alternative conduit. A recent meta-
analysis showed a patency rate of 46.9% after 5 years for
alternative autologous vein bypass grafts to infrapopliteal
arteries,12 but their limited availability, short length, gen-
erally poor quality, and tedious harvesting preclude their
widespread use.
Homografts have been used since the early years of
vascular surgery. Arterial allografts still have their place in
the replacement of infected aortic and femoral grafts, and
some authors have reported their use for distal reconstruc-
tion.16-18 On the basis of previous experimental work and
on their length and diameter, we opted for the use of
Fig 1. Kaplan-Meier analysis is shown for (Left) patie
10% at all points except from 96 months.homologous saphenous veins.5,7Different harvesting and preservation protocols can be
used for the storage of homologous veins: in a glycerol or
glutaraldehyde solution, in saline at 4°C or frozen at
70°C, or in liquid nitrogen at 196°C. These methods
differ in their ability to preserve the viability and structural
integrity of the tissue. We used a cryopreservation protocol
similar to the one used for other cells and tissues to preserve
their viability. Preservation of viable endothelial cells has the
advantage of also preserving the antithrombogenic properties
of the endothelium, which are important in the avoidance of
early graft thrombosis, especially in low-flow situations.
On the other hand, preservation of viable endothelium
has the disadvantage that the immunogenicity of the allo-
grafts is also preserved because vascular endothelial cells
express ABO and major histocompatibility complex class I
and II antigens. Carpenter et al19 could demonstrate an
immune response by activated T-lymphocytes (CD3, CD8,
CR3, and HLA DR Ag) containing cytotoxic granules
(TIA-1) after implantation of an allograft and showed that
ABO incompatibility was a significant risk factor for pa-
tency.
We counteracted the immune reaction byABO-matching
and low-dose immunosuppressants. Other preservation
techniques, such as preservation in glutaraldehyde, abolish
most of the antigenicity but also antithrombogenic prop-
erties. We based our choice on previous animal experi-
ments11 comparing different preservation protocols. In
these experiments, cryopreservation in combination with
low-dose immunosuppressive therapy with cyclosporine
rvival and (Right) limb salvage. Standard error (SE) isnt suyielded superior results.
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the accelerated deterioration of allografts by chronic rejec-
tion phenomena leading to enhanced intimal hyperplasia,
fibrosis, and aneurysmal degeneration as observed in many
studies.5 We also observed an accelerated degeneration of
the allografts with development of fibrotic stenoses or
aneurysms. These could, however, easily be treated by
Fig 2. Kaplan-Meier analysis is shown for (Left) primar
error (SE) is 10% at all points.excision with partial replacement of the allograft. The fre-quency of aneurysm formation in our series was far less
than the 20% observed by Streinchenberger,20 probably
because only saphenous veins of good quality were used
instead of veins collected from stripping. Our technique
differs from the technique used in many other studies
especially with regard to preservation technique and the
use of cyclosporine as immunosuppressive agent. Besides
ency and (Right) secondary patency rates. The standardy patcareful graft selection and patient follow-up, this might
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our series.
We tried to moderate the immense response by admin-
istering a low-dose immunosuppressive regimen with cy-
closporine for 1 year. Other immunosuppressive therapies
such as corticoids and azathioprine have also been used for
this purpose. Azathioprine has the disadvantage of induc-
ing bone marrow depression and newer immunosuppres-
sive therapy with rapamycin has an important influence on
wound healing, precluding its use for this indication. In our
experience, low-dose cyclosporine is very well tolerated and
can be used even in the presence of infection. The main
adverse effect of cyclosporine is its influence on renal func-
tion, but this only led to discontinuation in three patients.
Other adverse effects such as hypertension, edema, head-
ache, nausea, and diarrhea were only rarely observed and
resulted in only one patient discontinuing the therapy.
We discontinued cyclosporine treatment after 1 year
based on the observation that after that period the graft is
repopulated with host cells and immunosuppressive treat-
ment has become less important.8 With this protocol, the
side effects related to long-term treatment with immuno-
suppressive therapy can be avoided.
To compare our results with those of other groups, we
performed a literature review and gathered the results of all
published reports on venous allografts and their immuno-
suppressive therapy protocol (Table IV).21-39 Comparison
Table IV. Published cryopreserved allograft vein registries
Author Year No. Graft preservation Infra-p
Tice21 1972 25 Cryopreserved NM
Stephen22 1978 11 Cryopreserved
Ochsner23 1984 75 Cryopreserved 64
Sellke24 1989 6 Cryopreserved NM
Van Reedt Dortland25 1991 156 Cold storage 33
Deleersnijder26 1992 100 Cold storage 71
Brockbank27 1992 75 Cryopreservation 39
Trotter28 1993 17 Cryolifea NM
Walker29 1993 39 Cryolife 90
Shah30 1993 43 Cryolife NM
Harris31 1993 25 Cryograft 92
Martin32 1994 115 Cryograft 88
Posner33 1996 21 Cadvein NM
Lesèche34 1997 25 Cryopreserved 100
Rebane35 1997 107 Cold storage 63
Carpenter19 1998 40 Cryograft 93
Streinchenberger20 2000 170 Cold storage 26
Buckley10 2000 26 Cryograft 100
Harris L36 2001 80 Cryograft 75
Timaran37 2002 4 Lyophilized 100
Farber6 2004 240 Cryograft 75
Matia38 2007 46 61
Bannazadeh39 2009 66 Cryolife 80
Our results 2009 108 Cryopreservation 100
AZT, Azathioprine; CsA, cyclosporine A; FK 506, tacrolimus at drug leve
patency; SP, secondary patency.
aCryopreserved at 190°C.was made difficult because these grafts were used for differ-ent indications (some for replacement of infected grafts)
and because different methods of harvesting, preservation,
and immunosuppressive therapy were used. Through care-
ful graft selection, meticulous immunosuppressive therapy
with cyclosporine, and careful follow-up, we could obtain
1-year secondary patency comparable with the best pub-
lished results.
Our early amputation rate might seem high, but taking
into account that 16% of the patients had a contralateral
major amputation, 62% had a previous ipsilateral vascular
reconstruction, and 19% an extensive soft-tissue deficit with
osteomyelitis (Rutherford 6), our result seems very accept-
able and better than what could be obtained with synthetic
grafts. Our 5-year primary patency rate of 11.1% might also
seem low but resulted in limb loss in only 35% of the
patients after 5 years. This means that the allograft had
sufficient long-term patency to allow wound healing and
the development of collateral circulation. Many of these
allografts could be saved by a secondary intervention, re-
sulting in a 5-year secondary patency rate of 38.5%, which is
better than most long-term reports with polytetrafluoro-
ethylene for this indication. Therefore, cryopreserved GSV
allografts can be considered as an acceptable alternative to
prosthetic grafts. They are easy to harvest, have a suitable
length and diameter, are resistant to infection even with
immunosuppressive therapy, and can be implanted with
acceptable morbidity and mortality. The only nearly signif-
peripheral use
1-y patency, % 1-y LS, % Immunosuppression
48 84 None
10 None
50 SP (all) 75 AZT
33 100 None
71 SP 87 None
63 PP 85 None
79 PP NM CsA
71 SP 82 None
28 PP, 46 SP 67 None
66 NM None
36 SP 74 None
37 PP, 40 S 84 None
59.4 SP 62 CsA, AZT, prednisolone
52 SP 78 None
67 PP 69 None
13 42 AZT (1 mg/kg/d)
62.9 PP 86 None
87 PP 80 None
36.8 PP, 47 SP 69 None
7 mon, 25 25 None
30 PP 80 None
57 SP 71 37% prednisone; 46%
FK 506
10 PP, 42 SP 73 None
49.9 PP, 55.7 PAP,
73 SP
72 CsA
g/mL; NM, not mentioned; PAP, primary assisted patency; PP, primaryfor
op, %
%
%
%
%
%
%
.5
%
%
l 4-7 nicant risk factor for occlusion of allografts was the presence
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April 2010876 Randon et alof diabetes. As in some other recent studies, the use of
statins proved to have a positive influence on patency.
This study has some limitations. Although is a retro-
spective study over a long period of time and not a prospec-
tive randomized trial comparing other available alternatives
for GSV such as prostheses and other autologous material,
this limits the effect of the results. Further prospective
randomized work is needed to position the place of the
venous allograft in the algorithm for the choice of infrap-
opliteal conduits in CLI patients in the absence of autolo-
gous GSV.
CONCLUSION
We reviewed our 15-year experience with the use of
cryopreserved allografts in patients with severe CLI in need
of an infrapopliteal vascular reconstruction and without
suitable autologous saphenous vein. All patients were
treated with a low-dose immunosuppressive regimen with
cyclosporine. We obtained patency and limb salvage rates
that are at least comparable to rates for synthetic grafts used
for the same indication and to rates described in other
studies with venous allografts. Venous allografts have the
additional advantage of being infection resistant. Side ef-
fects of the 1-year immunosuppressive treatment were min-
imal. This study shows that following our protocol, venous
allografts constitute an acceptable alternative in patients
with CLI in need of an infrapopliteal bypass when no
autologous vein is available.
Better graft and patient selection, better graft surveil-
lance and immunologic matching, and standard intake of
statins could further improve the results. The major prob-
lems remain the availability of good quality veins for har-
vesting, the need for a tissue bank for preservation, and the
late rejection phenomena necessitating secondary interven-
tions to preserve patency.
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